Posts tagged John Hadden II
First UK-based clinical trial focused viral vector manufacturer announces launch
First UK-based clinical trial focused viral vector manufacturer announces launch

ViroCell Biologics, the primary clinical trial focused viral vector manufacturer within the UK, has introduced its official launch, with the intention of turning into the ‘supplier of choice’ for viral vectors and gene modified cells.

Read More
In the NewsFlorence BuchananCDMO, clinical trials, viral vectors, cell and gene therapies, ViroCell, Farzin Farzaneh, Truell Conservation Foundation, John Hadden II, gene therapy, cell therapy, CGT, UK CDMO, UR ALL news, vector design, AAV vectors, lentivirus vectors
First UK-based clinical trial focused viral vector manufacturer announces launch
First UK-based clinical trial focused viral vector manufacturer announces launch

ViroCell Biologics, the first clinical trial focused viral vector manufacturer in the UK, has announced its official launch, with the aim of becoming the ‘supplier of choice’ for viral vectors and gene modified cells.

Read More
In the NewsFlorence BuchananCDMO, ViroCell, Truell Conservation Foundation, Farzin Farzaneh, John Hadden II, gene therapy, cell therapy, CGT, viral vector, viral vectors, vector design, AAV vectors, lentivirus vectors, UK CDMO, PharmaJobs